Lexicon Pharmaceuticals (LXRX) Operating Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Operating Expenses for 17 consecutive years, with $22.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 17.98% year-over-year to $22.1 million; the TTM figure through Mar 2026 stood at $93.9 million (down 55.02% YoY), while the FY2025 annual figure was $98.7 million, down 56.74% from the prior year.
• Operating Expenses rose to $22.1 million in Q1 2026 per LXRX's latest filing, from $20.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $65.4 million in Q3 2024 and bottomed at $20.3 million in Q4 2025.
• Historically, Operating Expenses has averaged $36.6 million across 5 years, with a median of $30.3 million in 2022.
• Annual changes were most pronounced in 2023 — Operating Expenses surged 115.24% — and 2025, when it plunged 65.81%.
• Lexicon Pharmaceuticals' Operating Expenses stood at $30.3 million in 2022, then jumped by 56.53% to $47.4 million in 2023, then grew by 24.98% to $59.3 million in 2024, then slumped by 65.81% to $20.3 million in 2025, then climbed by 9.0% to $22.1 million in 2026.
• Business Quant data shows LXRX's Operating Expenses at $22.1 million in Q1 2026, $20.3 million in Q4 2025, and $26.4 million in Q3 2025.